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NOVEL IMAGING-BASED TECHNIQUES REVEAL A ROLE FOR PD-1/PD-L1 IN 
TUMOR IMMUNE SURVEILLANCE IN THE LUNG 
Todd Jacob Bartkowiak, B.S. 
Supervisory Professor: Tomasz Zal, Ph.D 
The binding of immune inhibitory receptor Programmed Death 1 (PD-1) on T 
cells to its ligand PD-L1 has been implicated as a major contributor to tumor induced 
immune suppression. Clinical trials of PD-L1 blockade have proven effective in 
unleashing therapeutic anti-tumor immune responses in a subset of patients with 
advanced melanoma, yet current response rates are low for reasons that remain 
unclear. Hypothesizing that the PD-1/PD-L1 pathway regulates T cell surveillance 
within the tumor microenvironment, we employed intravital microscopy to investigate 
the in vivo impact of PD-L1 blocking antibody upon tumor-associated immune cell 
migration. However, current analytical methods of intravital dynamic microscopy 
data lack the ability to identify cellular targets of T cell interactions in vivo, a crucial 
means for discovering which interactions are modulated by therapeutic intervention.  
By developing novel imaging techniques that allowed us to better analyze tumor 
progression and T cell dynamics in the microenvironment; we were able to explore 
the impact of PD-L1 blockade upon the migratory properties of tumor-associated 
immune cells, including T cells and antigen presenting cells, in lung tumor 
progression. Our results demonstrate that early changes in tumor morphology may 
be indicative of responsiveness to anti-PD-L1 therapy.  We show that immune cells 
in the tumor microenvironment as well as tumors themselves express PD-L1, but 
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immune phenotype alone is not a predictive marker of effective anti-tumor 
responses. Through a novel method in which we quantify T cell interactions, we 
show that T cells are largely engaged in interactions with dendritic cells in the tumor 
microenvironment.  Additionally, we show that during PD-L1 blockade, non-activated 
T cells are recruited in greater numbers into the tumor microenvironment and 
engage more preferentially with dendritic cells. We further show that during PD-L1 
blockade, activated T cells engage in more confined, immune synapse-like 
interactions with dendritic cells, as opposed to more dynamic, kinapse-like 
interactions with dendritic cells when PD-L1 is free to bind its receptor. By advancing 
the contextual analysis of anti-tumor immune surveillance in vivo, this study 
implicates the interaction between T cells and tumor-associated dendritic cells as a 
possible modulator in targeting PD-L1 for anti-tumor immunotherapy.       
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1. Introduction 
1.1 Immune surveillance 
 The theory that the immune system plays an important role in inhibiting 
malignant transformation and growth of the body’s own cells, tumor immune 
surveillance, was developed by Macfarlane Burnet from the 1950s to the 1970s (1-
3).  Robert Schreiber’s work (4, 5) further expounded the work of Burnet to uncover 
mechanisms by which tumors may escape immune surveillance and continue to 
grow.   
 In a broad context, immune surveillance (Figure 1)  as reviewed by Kupper 
and Fuhlbrigge (6) is the process by which immune cells in the peripheral tissue 
recognize and eliminate foreign pathogens that may be deleterious to the organism. 
The immune system is also able to recognize stress and/or damage signals given off 
by transformed tumor cells, and engulf altered self-antigens expressed by the tumor 
(3, 7).  Phagocytic cells in the peripheral tissue engulf these tumor-associated 
antigens (TAAs) and destroy transformed cells.  Occasionally, transformed cells can 
evade phagocytosis and continue to grow.  In these instances, an adaptive immune 
response must be initiated for tumor elimination (8). In order for the adaptive 
immune system to mount an anti-tumor response, tumor antigens engulfed in the 
tissue by antigen-presenting cells (APCs) must be presented to naïve T cells in the 
lymph node.  Upon engagement with antigen in the lymph node, T cells receive 
activation signals and are primed to respond to antigen in the peripheral tissue.  
Primed, mature T cells then leave the lymph node and enter the circulation in search 
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of the source of foreign antigen.  Following cytokine gradients, mature T cells 
extravasate into peripheral tissue and migrate to the tumor site.  Within the tumor 
site, T cells must maintain their activation state and begin to perform their effector 
function.  T cells can act in a supportive role to boost the anti-tumor response as is 
the case for CD4+ T cells,  in a cytotoxic response to kill the tumor, as is the case for 
a variety of cells including CD8+ T cells (9), or in a regulatory role to prevent 
unrestrained effector responses, as is the role of regulatory T cells (Tregs) in the 
tumor microenvironment (10).  
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Figure 1. 
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Figure 1. Components of immune surveillance.  Tumor immune surveillance is a 
multi-step process whereby the immune system is able to continuously recognize 
and eliminate malignant transformed cells in tissues.  1) Surveillance initiates when 
innate immune cells respond to stress/damage signals given off by tumor cells and 
engulf tumor antigens.  These cells then traffic to the lymph node to present tumor 
antigens to naïve T cells. 2)  Upon recognition of presented antigen, T cells receive 
activation signals before leaving the lymph node.  3) Once T cells leave the lymph 
node, they circulate throughout the body.  Following chemokine gradients, T cells 
must be recruited to the tumor site. Maintaining activation at the tumor site as well as   
migration around the tumor are important aspects of T cell anti-tumor responses.  
These aspects allow T cells to exert various effector functions in order to eliminate 
tumor cells.         
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1.2 Immune synapse formation 
 Presentation of tumor antigens to T cells in the lymph node is crucial to an 
adaptive immune response (6).  Antigen presentation occurs as T cells, through their 
T cell receptor (TCR), recognize foreign peptides presented by major 
histocompatibility complexes (MHC) on antigen-presenting dendritic cells (DC). Each 
T cell expresses a clonally distinct TCR that recognize specific epitopes on the 
antigen surface which must be recognized in the context of MHC.   
Clusters of TCR-MHC complexes form the immune synapse (11). The 
immune synapse is a major signaling complex through which T cells interact with DC 
to receive activation signals. The immune synapse consists of three distinct rings of 
supramolecular activating clusters (SMACs) on the T cell surface.  The central ring, 
the cSMAC consists of 1) TCR microclusters as well as 2) coreceptors (CD8 or CD4) 
necessary for stabilization of the TCR-MHC complex, and 3) costimulatory 
molecules (CD28, ICOS) that are necessary for propagation of a strong activating 
signal.  The peripheral SMAC (pSMAC) encircles the cSMAC and consists of 
adhesion molecules such as CD2 and leukocyte function associated antigen-1 (LFA-
1) which are spatially segregated from the cSMAC based dimension and which 
provide structural support to the synaptic complex.  The distal SMAC (dSMAC) 
surrounds the pSMAC and consists of very large phosphatase (CD43, CD44 and 
CD45) molecules that further support signaling at the immune synapse. The 
clustering of the molecules into discrete regions in the immune synapse allows for 
strong, stable interactions between T cells and APCs and efficient propagation of 
molecular signals resulting in T cell activation (12, 13). 
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Recent in vitro evidence, though, suggests that motile T cells do not always 
form strong, prolonged immune synapses with APCs. Loosely formed synapses are 
characterized by stretching of the SMAC regions as the synapse is dragged across 
the DC surface during T cell movement.  This type of interactions is termed the 
kinetic synapse or kinapse (14, 15). T cells in vitro that make strong receptor/ligand 
binding interactions at the synapse concomitantly reduce their motility in order to 
receive a full activation signal (16), however, T cells that form immune kinapses do 
not reduce their mobility, and as such form less stable, transient  receptor/ligand 
interactions that are easily and quickly broken.  These interactions occur as T cells 
move and slide across the surface of the APC and typically last on the order of only 
a few minutes as T cells receive weak activation signals (12).  T cell engagement in 
either  strong immune synapses or weak immune kinapses suggests a mechanism 
of activation by which T cells can either form long lasting synaptic signaling 
complexes with APCs to achieve full activation, or contrarily T cells may form short 
term kinaptic interactions with multiple APCs over a short time receiving only a 
partial activation signal from each APC which ultimately results in full T cell 
activation (12). While evidence suggests that T cells can form both synapses and 
kinapses in vivo (17), whether T cells makes these interactions in the context of 
tumors, and the role that PD-1/PD-L1 interactions play in forming these interactions 
in the tumor microenvironment is yet to be fully elucidated.  
1.3 Tumor immunogenicity 
 Regardless of the means by which T cells becomes activated, the adaptive 
response is largely dependent on the immunogenicity of the tumor; that is the ability 
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of the altered tumor antigens expressed by the tumor to elicit an immune response 
in the body.  Tumors can be classified based on how well they can provoke an 
immune response (18). Table 1 illustrates some of the varying degrees of tumor 
immunogenicity.  
 Highly immunogenic tumors elicit strong adaptive immune responses with 
large T cell infiltration.  Tumors in this category are rejected in naïve syngeneic hosts 
upon primary transplantation of tumors.  Subsequent transplantation of the same 
tumor type also leads to tumor rejection.     
 In contrast, tumors with intermediate immunogenicity are not rejected upon 
primary transplantation of tumor cells into naïve syngeneic hosts.  However, any 
subsequent transplantation of the same tumor cell line is rejected.  In this case, 
tumors trigger an adaptive response that is unable to effectively respond to the 
primary transplantation; however, upon secondary encounter T cells mount a potent 
anti-tumor response leading to rejection of any secondary transplantation. 
 Lastly, poorly immunogenic tumors, or tumors with no immunogenicity are not 
rejected when transplanted into naïve syngeneic hosts, nor are any subsequently 
transplanted tumor cells rejected.  Tumors that have low or no immunogenicity may 
evoke a small adaptive immune response if any adaptive response at all.       
 Our lab is interested in studying tumors with intermediate immunogenicity 
(Figure 2).  In particular, we are interested in the possible mechanisms by which an 
intermediate tumor can be recognized by the immune system and effectively killed, 
but by unclear mechanism(s) can evade the immune response.  To study potential 
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mechanisms of immune evasion in intermediately immunogenic tumors, we used an 
experimental model of metastasis which allows for tracking of tumor progression 
from a single cell stage.  Our tumor model is an MCA transformed fibrosarcoma 
which we show readily metastasizes, engrafts, and grows in the lung (Figure 2A). 
Evidence from our lab shows that tumors progress until overwhelming tumor burden 
in the lungs restricts lung function and turns lethal.  However, when naïve mice 
receive first a subcutaneous injection of MCA tumor cells, followed by a second 
intravenous injection of MCA cells, the majority of tumors are rejected in the lung 
(Figure 2B). Our evidence of the MCA immunogenicity is in line with other reports of 
the immunogenicity of MCA induced fibrosarcomas (19). In our model shown in 
Figure 2B, subcutaneous tumor burden leads to mortality, not tumor burden in the 
lung.   We also see T cell recruitment to MCA tumor nodules after the primary 
transplant, suggesting a mechanism of immune suppression in the tumor 
microenvironment. 
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Table 1.  Tumor immunogenicity  
Immunogenicity 
Primary 
Transplant 
Secondary 
Transplant 
Adaptive Immune 
Response 
High Rejected Rejected Yes 
Intermediate Not Rejected Rejected Yes 
None Not Rejected Not Rejected Maybe 
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Figure 2. 
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Figure 2. Methylcholanthrene induced MCA-205 fibrosarcoma represents an 
intermediately immunogenic cancer model. A) MCA-205 fibrosarcoma cells 
transduced with the tdimer (12) red fluorescent reporter were injected intravenously 
(IV), resulting in a robust growth of tumors in the lungs of naïve syngeneic mice, 
eventually leading to death.  B) However, similar IV injection of MCA cells into the 
mice that were, seven days earlier, implanted with MCA cells subcutaneously 
resulted in the rejection of cancer cells in the lung despite the continued growth of 
the subcutaneous tumors.    
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1.4. Tumor-mediated immune suppression 
 Tumors employ a host of mechanisms  to evade effective anti-tumor immune 
surveillance. Table 2 lists a few mechanisms by which tumors suppress immune 
responses, though this is by no means an exhaustive list. One mechanism of 
suppression involves recruitment of immune cells into the tumor microenvironment 
that can suppress T cell function. For instance, regulatory T cells recruited to the 
tumor microenvironment can express IL10 and TGF-β (10, 20) to inhibit T cell 
proliferation. Myeloid derived suppressor cells (MDSCs) and tumor associated 
macrophages (TAMs) recruited into tumor lesions can express inhibitory cytokines to 
inhibit anti-tumor responses as well pro-tumorigenic cytokines that help the tumor 
grow (21). Recent evidence also suggests that a population of dendritic cells (DC) 
recruited to the tumor microenvironment acquires a suppressive function (22-24). A 
second mechanism of immune suppression entails secretion of inhibitory molecules 
in the tumor microenvironment such as IL6 and IL10 by the tumor itself or by 
suppressive cells in the tumor microenvironment (25-27). 
A new and developing interest in the field of tumor immunology relates to the recent 
discovery that tumors can express various ligands for inhibitory receptors found on 
the T cell surface (28). Blockade of these inhibitory molecules may increase T cell 
activation and promote cancer cell killing by otherwise immune-suppressed T cells. 
Figure 3 shows several different inhibitory receptors found on T cells as well as their 
ligands present in the tumor microenvironment, though the exact mechanisms by 
which immune suppression is facilitated by the receptor/ligand interactions varies 
between receptor types (28). 
13 
 
Table 2. Mechanisms of tumor immune suppression 
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Figure 3. 
 
Figure 3. Inhibitory receptor/ligand interactions in the tumor 
microenvironment.  Ligands for inhibitory receptors expressed by T cells can be 
highly expressed in the tumor microenvironment and through different mechanisms 
lead to suppressed T cell responses.  For instance, either of the B7 molecules 
(B7.1/CD80 or B7.2/CD86) bind CTLA4, suppressing activation signals.  Similarly, 
CD80/PD-L1 interactions hamper T cell costimulation. Likewise, PD-1/PD-L1(2) 
interactions in the tumor microenvironment stifle T cell signaling cascades. 
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1.5. PD-1/PD-L1 interactions  
 Programmed Death Receptor-1 (PD-1) is a type I transmembrane protein 
consisting of an extracellular IgV domain, a transmembrane domain, and a short 
intracellular domain containing an immunoreceptor tyrosine-based inhibitory motif 
(ITIM) (29, 30). PD-1 is upregulated on monocytes (31), dendritic cells (24), 
regulatory T cells (32), some hematological tumors (33), activated B cells (34) and 
chronically activated/exhausted T cells (35). Upregulation and subsequent binding of 
PD-1 to PD-L1 during chronic activation leads to suppressed T cell signaling in the 
immune synapse. Src-homology region 2-containing phosphates-2 (SHP-2) has 
been implicated in binding and transportation of PD-1 into the central 
supramolecular activation cluster (cSMAC) in the immune synapse (36), where 
phosphorylated signaling complexes including zeta-chain associated protein kinase 
70 (ZAP-70) are dephosphorylated (Figure 4).  Disruption of the 
phosphatidylinositide 3-kinase (PI3K) pathway has also been implicated in 
dampening of T cell activation signal through PD-1 signaling (37).   
 Two ligands for PD-1 are currently known: Programmed Death Receptor 
Ligand-1 (PD-L1) and Programmed Death Receptor Ligand-2 (PD-L2). While PD-L2 
expression is restricted to dendritic cells (38-40), PD-L1 is more ubiquitously 
expressed on a variety of cells including antigen-presenting cells (41), T cells (42), 
endothelial cells (43), and on various tumor types (44, 45).  
PD-L1 is a type I transmembrane protein whose expression is regulated 
through a balance between interferon-gamma (IFNγ) signals (46, 47) and microRNA 
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activity (47). PD-L1 expressed on the cell surface not only binds to PD-1, but can 
also bind the costimulatory molecule CD80 which not only sequesters CD80 from 
making costimulatory interactions with CD28 on T cells, but this CD80/PD-L1 
interaction also inhibits T cell proliferation and effector responses (48-51).  
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Figure 4. 
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Figure 4. PD-1 dampens TCR signaling. Recognition and binding of peptide-MHC 
complexes by the T cell receptor propagates a weak activation signaling cascade 
through the T cell. Coreceptor molecules such as CD4 or CD8 stabilize 
TCR/peptide-MHC binding allowing for stronger, longer signaling.  Costimulation 
provided by CD28/CD80 binding further amplifies the TCR activation cascade.  
However, ligation of PD-1 on chronically activated T cells to PD-L1 allows for 
recruitment and binding of SHP-2 the ITIM motif of PD-1. This complex then moves 
into the immune synapse and dephosphorylates surface level signaling 
intermediates in the TCR signaling cascade.       
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1.6. Cancer immunotherapy by immune checkpoint blockade 
 Immune checkpoint blockade using antibodies to target inhibitory receptors or 
their ligands (28, 52) has proven effective in the treatment of several cancer types 
(53-56). Ipilimumab, an anti-CTLA4 blocking antibody has already been approved for 
the treatment of melanoma (57-59). In mice, anti-PD-1 and anti-PD-L1 antibody 
blockade has been shown to increase T cell activation in the lymph nodes of mice 
bearing B16 melanomas, leading to tumor regression  (60). Anti-PD-1 (55) and anti-
PD-L1 (56) antibodies are currently in Phase II clinical trials showing promising 
results in the treatment of advanced melanoma.  While patients receiving anti-PD-L1 
therapy have shown long-lasting clinical responses with few side-effects, response 
rates remain low.  In order to improve the efficacy of PD-L1 targeted 
immunotherapies, we seek to better understand the exact role of   PD-1/PD-L1 
interactions within the tumor microenvironment and how these interactions inhibit 
effective T cell immune surveillance.  
1.7. A need for novel methods to analyze tumor progression and anti-tumor 
immune responses.   
Current methods to study tumor progression and anti-tumor immune responses 
do not accurately reflect true tumor progression in vivo.  One current method to 
analyze tumor progression involves the genetic manipulation of mouse models to 
promote development of spontaneous tumors. In addition, these models require 
constant monitoring of tumor development. In these models, tumors growth is 
typically assessed using calipers to measure tumor dimensions over time.  However, 
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the tumor must be 1) visible and large enough to measure and 2) easily accessible 
for measurement.  Hence, the development of tumors prior to this point is largely 
unexplored using this method.  Microscopy can circumvent this limitation with the 
ability to image small tumors before they can be seen with the naked eye.  However, 
most microscopists are unconcerned with using microscopy to look at tumor 
development over time, and instead focus on events occurring at the tumor lesion.  
Our lab developed a novel imaging technique that allows us to visualize total tumor 
burden in an entire organ, the lung, whether tumors are microscopic or large enough 
to be seen.  By imaging the full lung tissue, we gain a better insight into the total 
amount of lung area taken up by the tumor.  In line with studying tumor progression, 
we also developed novel analyses, what we call the “tumor roundness index” to 
determine the effect of anti-PD-L1 blockade on tumor morphology. 
 Intravital microscopy (IM) is a valuable tool that has greatly enhanced our 
understanding of immune cell dynamics in the lymph node (61-63) as well as within 
the peripheral tissue (64, 65) and tumor microenvironment (66-68) .However, how 
and where T cells interact with other cells in vivo is poorly understood. Davis reviews 
mechanisms by which lymphocytes interact (69), but apart from molecular 
interactions, defining dynamic interactions in vivo has proven difficult. Interactions 
can be easily studied in vitro by looking at cell-cell binding interactions at the 
molecular level (15, 36, 70).  However, cell-cell interactions are more difficult to 
uncover in vivo.   In vivo, an interaction can be defined as a reduction in velocity 
(70), or by a local proximity to another cell concomitant with expression of effector 
molecules (64, 67).  Yet these methods do not take into account interactions which 
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may not provoke an effector response.  In our lab, we developed a novel method to 
analyze T cell interactions in the tumor microenvironment based on the longevity 
and localization of cell persistence, which we derive from the intensity-coded time 
projections of intravital motility recordings.  Using this method, we were able to 
discern areas where T cells were engaged for long periods with various interacting 
partners.  We could then quantify each interaction and then determine the effect that 
PD-L1 blockade had on these actions.  
1.8 Specific Aims 
We hypothesize that PD-1/PD-L1 interactions in the tumor microenvironment 
inhibit immune-mediated tumor destruction in part by modulating the spatiotemporal 
dynamics of T cell surveillance behavior.  To address this hypothesis, we first 
needed to develop more efficient imaging-based methods that would allow us to 
explore the effect of PD-L1 blockade on tumor burden and T cell dynamics in the 
tumor microenvironment. The intent of my thesis was therefore twofold: 
AIM 1: Develop novel imaging-based techniques to study tumor growth and 
immune cell interactions in the tumor microenvironment.  
AIM 2: Determine the effect of PD-L1 blockade on tumor progression and on 
immune cell dynamics in the tumor microenvironment.  
Development of these novel methods showed that tumors regress over a 
thirty day period when treated with anti-PD-L1 antibody.  The beginning of tumor 
regression appears to be concordant with a change in morphology and reduction in 
tumor area seen within one week of PD-L1 blockade.  Most importantly, using our 
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novel method to quantify T cell interactions in the tumor microenvironment, we 
showed that non-activated T cells are recruited in greater numbers during PD-L1 
blockade and these T cells make more preferential interactions with dendritic cells in 
the tumor microenvironment. Additionally, activated T cells are able to make more 
stable interactions with dendritic cells in the tumor microenvironment during PD-L1 
blockade.   
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2. Materials and Methods 
2.1 Mice  
C57BL/6 albino mice were purchased from the National Cancer Institute 
(Bethesda MD).  CD2-DsRed reporter mice were a kind gift from Dimitris Kioussis 
(MRC National Institute for Medical Research, London, UK) (71). IL2p8-GFP mice 
were a gift from Ellen Rothenberg (California Institute of Technology, Pasadena, CA) 
(72). CD11c-YFP mice were from Michel Nussenzweig (Rockefeller University, New 
York City, NY) (61). All transgenic mouse strains were bred on a C57BL/6 
background. Strains were interbred to produce a single mouse strain homozygous 
for all three fluorescent reporter transgenes.  Mice were maintained in a specific 
pathogen free facility, and all procedures carried were out in accordance with the 
guidelines established by the UT MD Anderson Institutional Animal Care and Use 
Committee. 
2.2 Cell lines 
The MCA-mCer cell line was generated by lentiviral transduction of the MCA-
205 C57BL/6 mouse fibrosarcoma cell line with the mCerulean fluorescent protein 
gene driven by the CMV promoter. The cDNA encoding mCerulean was a gift from 
David Piston (Vanderbilt, Nashville TN).  Mouse B16 melanoma cell were purchased 
from ATCC (Manassas, VA) and transduced with mCerulean by nucleoporation.  
Cells were cultured in IMDM media (Hyclon, ThermoScientific) supplemented with 
5% FCS, 50 μM β-mercaptoethanol, 6mM L-glutamine, 100 U/ml penicillin-G, and 
100μg/ml streptomycin. Cultures were grown in 5% carbon dioxide at 37oC. 
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2.3 Tumor injection and anti-PD-L1 therapy 
MCA-205 mCerulean cells were trypsinized and washed in HBSS before 
injection. Single cell suspensions of tumor cells were then injected intravenously into 
4-6 month old mice (3X105 cells per mouse).  After allowing the tumors to engraft 
and begin growing in the lung for seven days, PBS (control) or rat anti-mouse PD-
L1blocking antibody (10F.9G2, Bioxcell, West Lebanon, NH) was administered 
intravenously (100 µg/mouse in PBS) every two days for up to three weeks.   
2.4 Cell isolation from mouse lungs 
Lungs from tumor bearing mice receiving either anti-PD-L1 immunotherapy 
PBS as a control were finely chopped and digested in 10% Collagenase A and 
DNase 1 (10mg/ml) in IMDM supplemented with 5% FCS.  Lungs were digested for 
one hour in a 37oC incubator while rocking at 400 RPM.  Intact tissue was then 
passed through a pipette before being filtered through a 70μm cell strainer (BD 
Biosciences).  Filtrate was then washed three times in IMDM with 5% FCS and 
centrifuged at 1200RPM/4oC after each wash.  Cells were then stained for FACS 
analysis.  
2.5 Antibodies 
  The following antibodies were used for flow cytometry: CD11b-PerCP/Cy5.5 
(Mac-1a), CD11c-FITC (N418), F4/80-Pacific Blue (BM8), Ly6G-AlexaFluor647 
(AF647) (RB6-8C5), CD80-PE (16-10A1), and CD86-PE (GL1) were purchased from 
eBioscience (San Diego, CA). PD-1-AF647 (RPM1-30) and PD-L1-AF647 (MIH6) 
were purchased from AbD Serotec (Raleigh, NC). CD8-PerCP/Cy5.5 (53-6.7) and 
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CD4-APC/Cy7 (GK1.5) were purchased from BD Biosciences (San Diego, CA).  
CD69-AF647 (HI-2F3) and ICOS-AF647 (C398.4A) were purchased from Biolegend 
(San Diego, CA). Rat anti-mouse IgG2a, IgG2b, or Hamster anti-mouse Ig 
(eBioscience) were used as isotype matched control antibodies.  Rat anti-mouse 
CD16/CD32 (2.4G2, Fc-block, BD Biosciences) was used in all staining to block 
non-specific binding of antibody to Fc-receptors. 
2.6 Flow cytometry   
Two weeks after weaning, FACS analysis was performed on peripheral blood 
cells to verify fluorescence of the reporter genes.  Briefly, blood was drawn from tail 
veins, and red blood cells were lysed with distilled water for one minute, followed by 
administration of 10X PBS to stop lysis.  Cells were then stained with CD4-AF647 
antibody (GK1.5, eBioscience) to confirm fluorescence specificity.  Flow cytometry 
was performed on a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, 
CA).  
Cells from digested mouse lungs fifteen days after tumor injection were 
suspended in sterile IMDM supplemented with 5% FBS and blocked in Fc block 
(1:100) for 30 minutes before being washed three times. The cells were stained for 
one hour with various antibody combinations, including isotype-matched control 
antibodies, in sterile IMDM with 5% FBS, at 4oC.  Cells were then thoroughly washed 
in sterile IMDM with 5% FBS and analyzed on an LSR Fortessa flow cytometer 
equipped with lasers for 405, 488, 561, and 640 nm wavelengths and controlled by  
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BD FACSDiva v6.3.1 software (BD Biosciences).  All FACS analysis was performed 
using FlowJo software v10.0.5 (Treestar) on at least 5 mice per group.     
2.7 In vitro analysis of PD-L1 and MHC Class I upregulation on cancer cells in 
response to interferon γ  
3X105 cells were cultured with or without IFNγ (20U/ml) (from BD OptEIA 
mouse IFNγ ELISA set, BD Biosciences) for 48 hours before being trypsinized 
(0.05% trypsin, Fisher Scientific), washed in culture media and stained with anti-PD-
L1 antibody conjugated to AlexaFluor 647 (MIH6, AbD Serotec), anti-H2Kb antibody 
conjugated to FITC (AF6-88.5, Biolegend), or isotype controls. Flow cytometry was 
then performed using an LSR Fortessa flow cytometer (BD Biosciences, San Jose 
CA).   
2.8 Intravital Microscopy 
All imaging was performed using a TCS SP5 RS laser resonant scanning 
microscope (Leica Microsystems, Wetzlar Germany) equipped with lasers for 
405nm, 458nm, 488nm, 514nm, 543nm, and 633nm wavelengths.  Intravital imaging 
was performed on tumor-bearing control mice or mice receiving anti-PD-L1 
immunotherapy, all expressing various combinations of the CD2-RFP, IL2p8-GFP, 
and CD11c-YFP fluorescent reporter genes.  Individual mice were anesthetized with 
pentobarbital (0.1mg/g body weight) (Sigma Aldrich) for the duration of imaging.  
After one full one-hour-long movie was imaged, mice were sacrificed without 
recovery before subsequent mice were anesthetized and imaged. Lungs were 
excised, fixed for at least one hour in 4% formaldehyde, and stored in a 30% 
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sucrose solution for further imaging.  Anesthesia was maintained by administering 
diluted pentobarbital (0.6mg/ml) throughout the entire experiment via an infusion 
pump (Instech Solomon, Plymouth Meeting, PA).  Anesthetized mice were 
tracheotomized, intubated, and ventilated using a constant volume ventilator set at 
0.20 cc injection volume and 129 breaths per minute (BPM) (Inspira Harvard 
Apparatus, Holliston MA)   Mice were thoracotomized to open the chest cavity and a 
custom designed imaging apparatus was applied to the left lung.  The apparatus 
consisted of an imaging window attached to a thermo-regulator and vacuum suction.  
Mice were placed on a heated microscope stage maintained at 37oC during the 
entire acquisition. Intravital images were obtained through sequential excitation 
scanning using a 20X objective (HCPL APO 20X/0.70 NA, Leica Microsystems) 
attached to a piezoelectric focusing lens (Piezosystem Jena, Hopedale MA) allowing 
for optimal z-scanning every 20 seconds.  Images were acquired using 8-bit 
resolution, 512 pixel X 512 pixel dimension, with sequential scanning in x,y,z and 
time dimensions such that a full z-scan was acquired sequentially in each channel.  
To minimize bleed-through of fluorescent emission, green fluorescence emission 
was acquired separately from yellow fluorescence emission.  Red and blue 
fluorescence were acquired concurrently. All images were taken using a zoom = 1.7, 
z-step size = 2 µm, and pinhole = 106 µm. Single one-hour-long movies were taken 
per mouse in at least 3 and up to 5 mice per group. 
2.9 Ex-vivo imaging  
To image entire lung lobes, mice were sacrificed and lung lobes were excised 
before being gently washed in PBS and mounted to a cover slide.  Images were then 
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taken using a 4X objective (XLFluor 4x/360, 0.28NA, Olympus NDT Inc, Waltham 
MA).   
To image lung tissue after intravital imaging, lungs were harvested from 
euthanized mice and fixed for a minimum of one hour in 4% formaldehyde (Sigma 
Aldrich, St. Louis MO), then washed in PBS and soaked in 30% sucrose in PBS 
before static images were taken using a 20X objective (HCPL APO 20X/0.70 NA, 
Leica Microsystems).  
2.10 Image processing and motility analysis 
Images were processed using the Leica Application Suite version 1.7.0 build 
1240 (Leica Microsystems).  Briefly, maximum intensity projections were created 
from all images. If spectral bleed-through was detected, linear unmixing was 
performed in each channel. To reduce noise, median filtering was performed using a 
filter width of 3.   
To obtain percent tumor coverage, whole lung images taken from a minimum 
of three mice/group/day using a 4X objective (XL Fluor 4X/340 Olympus, NA=0.28) 
were stitched together in Photoshop (Adobe Photoshop CS4 Extended v11.0.2, 
Adobe Systems Incorporated).  Tumor morphology parameters were obtained in 
Slidebook version 5.0 (Intelligent Imaging Innovations, Denver CO) using Ridler-
Calvard thresholding with manual correction if needed. Total tumor area was 
compared to total lung area to acquire percent tumor coverage.  Intensity-based 
masks were acquired from at least 15 thresholded images taken from at least 3 mice 
with a 20X objective (HCPL APO 20X/0.70 NA, Leica Microsystems) to find tumor 
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area and tumor roundness.  Tumor roundness was obtained using the following 
equation:   
 
where R= tumor roundness A= tumor area and P= tumor perimeter. 
T cell densities were acquired from static images by first enumerating the number of 
T cells in the image and normalizing to tumor area.   
Intravital movies were processed in the Leica Application Suite as above.  
Tracking analysis was performed in Imaris v 7.5.1 (Bitplane, South Windsor CT). If 
necessary, movies were corrected for translational drift and smoothed for time using 
a filter width of 2.  Cells were tracked using spot detection with a diameter of 10 μm.  
Tracks persisting for less than half of the movie time were excluded from analysis. 
Spider-plots were created by translating cell tracks to a common origin.   
2.11 Analysis of T cell interactions  
Analysis of T cell interactions was performed using the Leica Application 
Suite version 1.7.0 build 1240 (Leica Microsystems).  An interaction was defined as 
a cell lacking translational motility within a confined area less than or equal to the 
cell’s own diameter for at least 10 minutes.  To detect the sites of cell immobilization 
based on three-dimensional intravital motility recordings, we devised the multi-step 
protocol as follows. The raw 3-D time lapse recordings were first thresholded and 
binarized such as to convert the variable fluorescence intensities to intensity-
independent cell shapes whose pixel intensities were equal to 1 whereas the non-
30 
 
cell pixel intensities were equal 0. Next, the binarized time lapse data sets were 
processed to generate two types of time projections: the average intensity time 
projection multiplied by the constant factor 256 (AITP) and the maximum intensity 
time projection (MITP). The AITP image has the important property that the pixel 
intensities represent the duration of cell persistence in the area. For example, an 
intensity of 256 indicates that a cell spent 100% of its time in a location and an 
intensity of 128 indicates that a cell spent 50% of its time in said location. The MITP 
image represents all places visited by cells during intravital motility recording. To 
detect the sites of cell persistence for 10 min or longer in a 60 min long recording, 
the AITP image was thresholded at a pixel intensity value equal to 43 in an 8-bit 
image. This intensity value corresponded to the ten minutes of a one-hour-long 
movie according to the formula 10 min = 60 min x 43/256. The thresholded AITP and 
MITP images were then merged into a single two-color image. The areas of overlap 
represent areas of protracted immobility of 10 or more minutes in relation to all areas 
of cellular motility.  The image representing the sites of T cell persistence were then 
overlaid over the images of other cells that were visualized during intravital 
recording, such as tumor cells or dendritic cells, and the overlaid composite images 
were inspected. Sites of persistence were categorized based on the type of 
immediately adjacent neighboring cells.  Interaction was defined as T cells persisting 
with thresholded overlaps within one T cell length around a potential target. Analysis 
of T cell interactions was performed on 4 movies from 4 mice per treatment and 
control groups.           
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2.12 Statistical analysis 
All statistical analysis was performed in Graphpad Prism version 5.03 (Graphpad 
Software). Bar graphs show mean ? standard deviation unless otherwise indicated. 
Bars in scatter plots show median values. Arrest coefficient was defined as the 
proportion of time a T cell maintained an instantaneous velocity below 1.5 μm/min.  
Statistical significance was determined using a non-parametric Mann-Whitney U test 
or unpaired Students’ T to compare differences between groups.  P-values less than 
0.05 were considered significant.   
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Results 
3. Effect of PD-L1 blockade on tumor growth and immune phenotype 
3.1 Whole-lung image analysis revealed therapeutic antibody blockade of PD-
L1 reduces MCA tumor burden in mouse lungs.   
To determine the effect elicited by anti-PD-L1 blockade therapy, four to six 
month old C57BL/6 mice were intravenously injected with 3 X 105 MCA-mcer 
fibrosarcoma tumor cells.  One week was given for tumors to engraft in the lung 
before anti-PD-L1 blocking antibody (10F.9G2) was administered (100ug/mouse, 
given intravenously every other day), for up to one month post tumor injection 
(Figure 5A).  Tumor burden was then assessed in excised lungs using image-based 
analysis (Figure 5B and C) to determine the percent of total lung area covered by 
the fluorescent tumors.  A few small tumors were visible in the lung after 8 days post 
tumor injection (arrows in figure 5B, day 8) in both anti-PD-L1 treated mice and 
untreated controls. Percent lung coverage by tumors then increased up to day 15 
post tumor injection (8 days of treatment in the experimental group). Tumor burden 
continued to increase in control mice, however, after 15 days post injection tumor 
burden in the lungs of treated mice leveled off and began declining after 23 days 
post tumor injection (p = 0.0544) (Figure 5B and 5C).  At this point, tumors were 
visible to the naked eye in untreated mice, but were microscopic in treated mice 
(Figure 5C, inset). Twenty nine to thirty days post injection, tumors from untreated 
mice covered an average 14.04% of the entire lung. These mice were under severe 
respiratory distress as evidenced by heavy breathing and lethargy (data not shown).  
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However, mice treated with anti-PD-L1 blocking antibody had only one or two small 
tumors covering 0.369% of the lung (p = 0.0004).  These mice were active and 
showed normal breathing patterns (data not shown).  Together these data 
demonstrate that anti-PD-L1 blockade therapy is effective in reducing MCA 
fibrosarcoma tumor burden in mouse lungs. 
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Figure 5. 
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Figure 5. Anti-PD-L1 antibody blockade reduced MCA tumor burden in the 
mouse lung.  A)  Four to six month old mice were injected intravenously with 3X105 
MCA-205 mCerulean tumor cells. After seven days, mice were treated with anti-PD-
L1 blocking antibody (10F.9G2) or PBS (control) every other day for up to three 
weeks (top arrows).  Lungs from tumor-bearing mice were excised on a weekly basis 
(bottom arrows) to ascertain tumor burden with or without treatment. B) Micrographs 
were taken using a 4X (0.28 NA) objective, z-step = 10 μm. Lung sections were 
compiled in Adobe Photoshop to image the full lung (outlined).  Bright green 
fluorescence indicates tumor nodules in the lung. White arrows indicate small tumor 
nodules.  C) Tumors from untreated mice were clearly visible as large macroscopic 
nodules (inset) on the lungs (black arrow heads) as early as 23 days post tumor 
injection, whereas no large nodules were visible in mice treated with PD-L1 blocking 
antibody. Tumor burden was quantified as percent of total lung area covered by 
tumors.  Tumor area and lung area were calculated using intensity-based masks in 
Slidebook software.  Arrows indicate time of tumor injection and treatment 
respectively.  Comparisons of tumor coverage between untreated (Control, blue line) 
and treated (αPD-L1, red line) were made using an unpaired Students’ T Test. N=3 
mice/group/day.  Error bars represent mean +/- standard deviation. ***= p<0.001.         
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3.2 A change in tumor morphology after 8 days of PD-L1 blockade.  
We were interested in probing deeper into anti-tumor events occurring around 
fifteen days post tumor injection (eight days after the initiation of anti-PD-L1 
therapy), as this appeared to be a critical time point before tumors began to regress 
in mice treated with anti-PD-L1 blockade therapy.  To further study this time point, 
we first looked more closely to see if PD-L1 blockade had a noticeable effect on 
tumor morphology at this time point in the treatment protocol.  
Visualizing tumor cells under a higher magnification objective (20X/0.70 NA) 
allowed for detection of finer details of individual tumors.  Using a higher power 
objective, we could see a subtle difference in tumor morphology after 8 days of anti-
PD-L1 blockade.  Tumors in control mice had more jagged edges that extended into 
the lung tissue, consistent with the invasive phenotype of progressing fibrosarcoma 
tumors (Figure 6A, left).   In contrast, tumors in the lungs of mice treated with anti-
PD-L1 therapy for 8 days had smoother edges and fewer extensions into the 
surrounding lung tissue (Figure 6A, right).   
First quantifying the tumor area using higher magnification, we found that 
median tumor area was significantly lower after PD-L1 therapy (p = 0.0075) (Figure 
6B).  This difference in tumor area, but not total lung coverage (Figure 6C), was not 
due to an increase in the number of tumors present in the lung (Figure 6C), but was 
most likely due to an increase in image resolution due to use of a higher power 
objective.  Inserting tumor area into the formula for roundness (see methods), we 
found that after 8 days of therapy, tumors were significantly more round than tumors 
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from untreated mice (p = 0.046) (Figure 6D). Together, these data suggest that PD-
L1 blockade is affecting tumor growth in the lung within eight days of treatment by 
containing tumor nodules and limiting tumor invasiveness. 
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Figure 6. 
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Figure 6:  Effects of anti-PD-L1 blockade on tumor morphology were seen after 
8 days of immunotherapy.  A) Tumors from mice treated for 8 days with anti-PD-
L1 antibody (right) had a different morphology than untreated mice (left).  This 
morphology was characterized by smoother edges and fewer protrusions into the 
surrounding lung tissue. Representative micrographs from n=15 tumors/group from 
either untreated (left) or treated (right) mice fifteen days post tumor injection. Scale 
bar = 100 μm. Micrographs were taken using a 20X objective. B) After 8 days of 
anti-PD-L1 antibody blockade, enhanced resolution imaging showed tumors from 
treated mice were significantly reduced in area compared to tumors from untreated 
mice. C) However, the number of tumors engrafted in the lung within 15 days of 
tumor injection was not significantly different. D) Tumors from mice receiving anti-
PD-L1 antibody had a significantly more round morphology than tumors from 
untreated mice. Statistical significance was determined using a Mann-Whitney U 
Test. Data collected from at least 15 tumors from a minimum of 3 mice per group. 
Bars represent median values. * = p < 0.05, ** = p< 0.01. 
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3.3. PD-L1 was expressed by MCA fibrosarcoma tumor cells and tumor-
associated stromal cells.   
 Next, we sought to determine potential cellular targets expressing PD-L1 that 
may be affected by anti-PD-L1 blockade.  To determine which cells in the tumor 
microenvironment express PD-L1, we harvested lungs from mice 15 days post tumor 
injection, digested the lungs according to established protocols (see methods) and 
stained for fluorescent markers.  Cells were gated based on their expression of cyan 
fluorescent protein (CFP) expressed by all tumors and PD-L1. Roughly 9% of non-
tumor stromal cells express PD-L1in the lung, whereas less than 2% of tumor cells 
express PD-L1 (Figure 7A).  This finding was in contrast to experiments in vitro 
which showed that PD-L1 is expressed at very low levels on MCA fibrosarcoma cells 
compared to a B16 melanoma model that expresses high levels of PD-L1 (Figure 
7B).  However, in agreement with several reports that demonstrate upregulation of 
both MHC (73) and PD-L1 (46, 74) in the presence of interferon gamma (IFNγ), 
MCA fibrosarcoma cells upregulated both MHC-I (H2-kb) and PD-L1 when stimulated 
with IFNγ in vitro (Figure 7C). 
 It is of great interest to note that PD-L1 was expressed to a much greater 
degree on non-tumor cells than tumors themselves in the lung.  To determine 
whether these PD-L1+ stromal cells had an impact in the local tumor 
microenvironment we stained lungs with anti-PD-L1 staining antibody (MIH6, 
conjugated to Alexa Fluor 647).  PD-L1+ stromal cells densely populated the tumor 
microenvironment, and a subset of PD-L1+ cells were also positive for the CD11c-
YFP transgenic reporter construct (Figure 7D, yellow arrows).  Together, these 
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data show that MCA fibrosarcoma cells can upregulate PD-L1in the presence of 
IFNγ, suggesting that IFNγ secreting T cell and NK cells in the tumor 
microenvironment may act as a mechanism by which PD-L1 is upregulated on 
tumors in vivo (75). This data also shows that MCA fibrosarcomas are not the only 
cell type in the tumor microenvironment that may express PD-L1 indicating that  PD-
L1+ cells, potentially of myeloid origin, may play a role in inhibiting effective anti-
tumor immune responses.  
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
Figure 7. 
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Figure 7: PD-L1 is expressed both on tumor cells and tumor-associated 
stromal cells.  A) C57BL/6 mice were injected with 3X105 MCA fibrosarcoma cells. 
Fifteen days later, lungs were harvested and digested according to established 
methods to release cells for further analysis.  Cell suspensions were then stained 
with PD-L1-AF647 antibody to determine PD-L1 expression.  Tumor cells were 
gated based on CFP fluorescence expression (y axis) and PD-L1 expression (x 
axis). A small subset of CFP+ tumor cells expressed PD-L1; however, a much larger 
percent of non-tumor stromal cells expressed PD-L1 compared to tumor. This PD-
L1+ stromal cell subset is present in the normal lung without the presence of tumors. 
B)  In vitro cultured MCA fibrosarcoma or B16 melanoma were stained with anti-PD-
L1 fluorescent antibody. Compared to B16 (orange curve), MCA (red curve) 
expresses very low levels of PD-L1.  (Isotype control in blue).  C)  When cultured for 
48 hours with IFNγ (20U/ml), MCA cells were able to upregulate MHC-I (H2-Kb) and 
PD-L1. Blue curve = isotype, red curve = MCA cells, green curve = MCA cultured 
with IFNγ.  D) Lung tissue stained with anti-PD-L1 antibody showed an abundance 
of PD-L1+ stromal cells within the tumor microenvironment, some of which where 
dendritic cells (yellow arrows). (Blue = tumor, red = T cells, green = dendritic cells, 
white = PD-L1). In vivo PD-L1 expression was performed on a minimum of 2 mice.  
In vitro MHC and PD-L1 expression was performed on three independent 
experiments with at least 2 replicates.          
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3.4. Anti-PD-L1 antibody therapy reduced available PD-L1 but did not alter 
expression of costimulatory molecules on myeloid cells. 
 We were next interested in the effect PD-L1 antibody blockade had on PD-
L1+ stromal cells in the tumor microenvironment.  Several different myeloid cell 
populations express PD-L1 including myeloid derived suppressor cells (MDSCs) and 
tumor-associated macrophages (TAMs)(21), inflammatory dendritic cells, and 
conventional dendritic cells (cDCs) (76).  All four of these cell types have been 
shown to suppress the immune response in the tumor microenvironment and aid 
cancer progression (23, 24, 77, 78). 
 Of primary interest was the effect of PD-L1 blockade on the ability of these 
myeloid populations to suppress T cell function in the tumor microenvironment.  We 
first tested how PD-L1 blockade influenced the proportion of these suppressive cells 
in the lung tissue.  To ascertain the role of PD-L1 on myeloid cells, we harvested 
and digested lungs from tumor bearing mice 15 days post tumor injection.  First, 
gating on large cells, (Figure 8A, left), we next investigated the proportions of 
myeloid cells in the lung based on expression of CD11b and CD11c.  Using these 
markers, we found three distinctly different cell populations: CD11b+CD11c-, 
CD11b+CD11c+, and CD11b-CD11c+.  CD11b+CD11c- cells were differentiated by 
expression of F4/80 and Gr-1 (Ly6G).Specifically, CD11b+CD11c-F4/80+Gr1high 
cells were consistent with the phenotype for  MDSC (77), and CD11b+CD11c-
F4/80+Gr1low was a phenotype for TAMs (78).  Expression both  CD11b and CD11c 
was phenotype consistent with  inflammatory DC (22, 76) and a CD11b-CD11c+ 
phenotype was  consistent with cDCs (76) (Figure 8A).   
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 We found that while 70% of CD11b+CD11c- cells were MDSCs, eight days of 
anti-PD-L1 blockade did not alter the proportion of MDSCs in the lung (p = 0.0688). 
Tumor-associated macrophages made up 28% of the CD11b+CD11c- cells, and PD-
L1 blockade again did not affect the proportion of these cells in the lung (p = 
0.1057).  Inflammatory dendritic cells made up less than 1% of myeloid cells in the 
lung and conventional DC made up 2% of myeloid cells. Again, anti-PD-L1 blockade 
did not significantly impact proportions of either of these populations into the lung (p 
= 0.9938 and 0.4407 respectively) (Figure 8B). 
 While PD-L1 blockade did not affect the proportion of myeloid cells in the 
lung, we hypothesized that blockade would affect the ability of myeloid cells to 
stimulate T cells in the tumor microenvironment particularly in the expression of 
costimulatory molecules (CD80 and CD86) and coinhibitory molecules (PD-1 and 
PD-L1).  A small portion of MDSCs (Figure 8C), expressed the costimulatory 
molecules CD80 and CD86 at low levels. Anti-PD-L1 therapy did not significantly 
alter the CD80+ nor CD86+ populations within the lung (p = 0.2145 and p = 0.4567 
respectively) nor did therapy alter the expression level of CD80 or 86 at the cellular 
level as indicated using mean fluorescence intensity values (MFI) (p = 0.7304 and  
0.7879 respectively). Roughly 20% of MDSCs in the lung expressed PD-1, however, 
anti-PD-L1 blockade did not significantly alter the proportion of PD-1+ MDSCs (p = 
0.5588) nor PD-1 expression on a per cell basis (p = 0.6891).  On the other hand, 
PD-L1 was expressed on 34% of MDSCs in the lung. During PD-L1 blockade, 
however, only 11% of MDSCs expressed PD-L1 (p = 0.0005).  However, PD-L1 
expression was not significantly altered on a per cell basis (p = 0.5588).   
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 Much like MDSCs, tumor associated macrophages in the lung did not 
significantly alter CD80, CD86 or PD-1 expression either.  Less than 10% of TAMs 
expressed CD80 or CD86, and the percent of TAMs expressing either CD80 or 
CD86 was not significantly altered by therapy (p = 0.142 and 0.7546 respectively).  
TAM expression of neither CD80 nor CD86 was altered on a per cell basis either (p 
= 0.5476 and 0.5728 respectively).  The TAMs expressing PD-1 were similarly 
unaltered during PD-L1 therapy (p = 0.1949), nor was PD-1 expression significantly 
altered on a cell to cell basis (p = 0.0946).  Roughly 43% of TAMs expressed PD-L1 
within the lung. This number was significantly reduced after 8 days of anti-PD-L1 
blocking therapy to 12% of TAMs expressing PD-L1 (p = 0.0019).  However, MFI 
values showed that PD-L1 were not significantly reduced by therapy on a per cell 
basis (p = 0.0632).   
 Next, we analyzed the effect of anti-PD-L1 blockade on the ability of the 
inflammatory DC subset of myeloid cells to provide costimulation to T cells (Figure 
8E).  While roughly half of inflammatory DC expressed CD80 and CD86 (50.56% 
and 47.57% of cells respectively), eight days of anti-PD-L1 therapy did not 
significantly alter the proportion of the CD80+ (p = 0.5495) nor the proportion of 
CD86+ (p = 0.3357) inflammatory DCs in the lung. Looking at MFI values, the 
expression of CD80 and CD86 on a per cell basis was also not significantly altered 
by anti-PD-L1 therapy (p = 0.9476 and p=0.4061 respectively). Over 70% of 
inflammatory DCs expressed PD-1, but the levels of PD-1+ inflammatory DC were 
not significantly altered when mice were treated with anti-PD-L1 blocking antibody 
for eight days (p = 0.2587). The PD-1 mean fluorescence intensity was also not 
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significantly altered by therapy (p = 0.4061) indicating that PD-1 was not significantly 
downregulated due to therapy.  PD-L1+ inflammatory DC were prevalent within the 
lung tissue with 90% of inflammatory DC expressing PD-L1.  After eight days of PD-
L1 blockade, the PD-L1+ inflammatory DC population significantly dropped to only 
63% of inflammatory DC expressing PD-L1 (p = 0.0014).  The MFI of PD-L1 was 
also significantly lower in the treated group p = 0.0028 indicating that PD-L1 was 
being blocked on a per cell basis.    
 Half of conventional dendritic cells (cDCs) expressed CD80 and 30% 
expressed CD86 (Figure 8F). Similar to other myeloid populations, the CD80+ cDC 
population was not significantly altered by PD-L1 therapy p = 0.2247. This was also 
evident on at the cellular expression level (p = 0.7349). Akin to the effect of PD-L1 
blockade on CD80 expression, the CD86 cDC population was not significantly 
altered as a percent of the total population (p = 0.4597) or on a cell by cell basis (p = 
0.6649) as a result of eight days of treatment. PD-1 was expressed on an average of 
58% of cDCs, but the proportion of cDCs expressing PD-1 was not significantly 
altered within eight days of therapy (p = 0.5362, not was PD-1 expression altered on 
a per cell basis (p = 0.2799).  The majority of conventional DC (over 70%) expressed 
PD-L1. Anti-PD-L1 blockade significantly reduced the PD-L1+ cDC population in the 
lung to 42% of cDC (p = 0.0051).  Looking at mean fluorescence intensity, PD-L1 
blockade also significantly reduced PD-L1 expression on cDCs on a cell-by-cell 
basis (p <0.0001).  Taken together, our data shows that PD-L1 blockade effectively 
reduced PD-L1 on myeloid cell populations in the lung without altering expression of 
B7 costimulatory molecules or the coinhibitory molecule PD-1.  We also showed 
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limited expression of B7 costimulatory molecules on MDSCs and TAMs consistent 
with poor antigen presentation capability, which was unaffected by PD-L1 blockade.  
However, a higher proportion of both inflammatory DCs and cDCs expressed the B7 
costimulatory molecules consistent with elevated antigen presentation capability by 
dendritic cells.  These data suggest that eight days of therapy has limited effects on 
the capacity of myeloid cells in the lung to stimulate T cells, though at least one 
mechanism of T cell suppression was abated.  
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Figure 8. Anti-PD-L1 antibody blockade reduced available PD-L1 in the tumor 
microenvironment. A) Lung tissue was taken from tumor-bearing mice treated with 
either PBS or anti-PD-L1 antibody for 7 days. Cell suspensions were then FACS 
sorted based on CD11b and CD11c expression. CD11b+CD11c- cells were then 
further sorted based on expression of F4/80 and Ly6G (Gr-1).  A CD11b+CD11c-
F4/80+Gr-1high phenotype was consistent with myeloid derived suppressor cells 
(MDSC).  A phenotype of CD11b+CD11c-F4/80+Gr-1low was consistent with tumor-
associated macrophages (TAMs). A phenotype of CD11b+CD11c+ was classified as 
inflammatory dendritic cells, whereas a CD11b-CD11c+ phenotype classified cells 
as conventional DCs (cDCs). B) Eight days of PD-L1 treatment did not significantly 
alter the proportion of the MDSC, macrophage, inflammatory DC or cDC populations 
in the lung. Eight days of anti-PD-L1 blockade therapy did not significantly alter 
CD80 expression, CD86 expression nor PD-1 expression on MDSC (C) TAM (D) 
Inflammatory DC (E) or conventional DC (F).  However PD-L1 expression was 
significantly reduced on all four populations tested. Analysis was performed on n=6 
mice per group. Significance was determined using a Mann-Whitney U-Test.  Error 
bars indicate mean +/- standard deviation.  ** = p<0.01, ***= p<0.001, ns= not 
significant.  
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3.5 Anti-PD-L1 blockade increased the presence of T cells in the tumor 
microenvironment, but did not affect T cell activation in the lung. 
 Considering that PD-L1 blockade had little effect on the expression of 
costimulatory molecules by myeloid cells, we next hypothesized that a reduction of 
available PD-L1 in the tumor microenvironment during therapy would tip the balance 
between positive and negative signaling and modulate T cell activation in the tumor 
microenvironment.  To deduce any effect, we first looked at whether PD-L1 blockade 
therapy affected recruitment of T cells into the tumor microenvironment.  T cells 
formed distinct halo patterns around tumors regardless of treatment (Figure 9A), 
however, eight days of anti-PD-L1 therapy significantly increased the average 
density of non-activated (CD2-RFP+) T cells surrounding the tumor (12 cells/2500 
sq. μm in untreated mice vs. 27 cells/ 2500 sq. μm in treated mice, p = 0.0011) 
without significantly altering the density of activated (IL2p8-GFP+) T cells (8 
cells/2500 sq. μm in untreated mice vs. 6 cells/2500 sq. μm in treated mice, p = 
0.5478). The ratio of activated to non-activated T cells in the tumor 
microenvironment remained unchanged during therapy (p = 0.5932) (Figure 9A).   
We next sought to determine the phenotype of the non-activated (CD2-RFP+) 
during PD-L1 blockade, particularly if these cells were CD8+ cytotoxic T cells or 
CD4+ helper T cells.  To determine if PD-L1 blockade had any effect on the 
presence of CD8+ or CD4+ T cells in the lung fluorescent MCAmcer tumor cells 
were injected into transgenic mice expressing the CD2-RFP reporter transgene.  
Fifteen days post tumor injection (and after 8 days of therapy) we performed FACS 
analysis by gating on RFP-high cells before analyzing the  CD4+ and  CD8+ 
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populations (Figure 9B).  Twenty percent of RFP-high cells in the lung were CD4+, 
and 22% of RFP-high cells were CD8+. After 8 days of anti-PD-L1 blockade, neither 
the percent of CD4+ nor CD8+ RFP-high populations in the lung dramatically 
changed (p = 0.6543, and p = 0.3892, respectively) nor was the ratio of CD8+ to 
CD4+ T cells in the lung altered  by treatment (p = 0.1092).     
In order to better understand the effects of anti-PD-L1 therapy upon the states 
of activation of tumor-associated T cells, besides using the IL2-promoter-GFP 
reporter of T cell activation, we also assessed lung T cells for the levels of 
expression of other markers of activation.  In particular, using flow cytometry, we 
measured  expression of the CD69 C-type lectin as an early activation marker (79), 
inducible T cell costimulator (ICOS) as a marker of intermediate activation (80), and 
PD-1 as a marker of chronic activation. CD4+CD69+ T cells made up 29% of the 
total CD4+ T cell population, but the  proportion of CD4+CD69+  T cells was not 
significantly altered after eight days of therapy (p = 0.9169), nor was CD69 
expression altered on a per cell basis based on MFI (p = 0.8182). ICOS was 
expressed on 48% of CD4+ T cells in the lung, but ICOS was not significantly altered 
after  eight days of therapy either as a portion of total CD4+ T cells expressing ICOS 
(p = 0.3429) or on a per cell basis as indicated by mean fluorescence intensity (p = 
0.1143).  We found that 32% of CD4+ T cells in the lung expressed PD-1.  The 
percent of CD4+ T cells expressing PD-1 was unchanged by anti-PD-L1 therapy (p = 
0.4206) (Figure 9C).  MFI was also not significantly different after administering 
therapy (p = 0.9372) indicating that therapy had no effect on the expression of PD-1 
on a per cell basis. 
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Subsequently, we investigated the effect of PD-L1 therapy on expression of 
these activation markers on CD8+ T cells (Figure 9D). CD8+CD69+ T cells 
accounted for 25% of CD8+ T cells in tumor bearing mice. During PD-L1 treatment, 
the percent of CD8+CD69+ T cells in the lung remained unchanged (p = 1.00), as 
did CD69 expression on a cell-by-cell basis (p = 0.5368).   We found that 29% of 
CD8+ T cells expressed ICOS in the lungs of tumor bearing mice. Anti-PD-L1 
blockade therapy did not affect the proportion of CD8+ T cells expressing ICOS (p = 
0.4857), nor ICOS expression on a cell by cell basis when analyzing MFI (p = 
0.400). Analyzing PD-1 expression, we found that 23% of CD8+ T cells in the lung 
expressed PD-1 fifteen days after tumor injection. The percent of CD8+PD-1+ T 
cells in the lungs of tumor bearing mice remained unchanged during PD-L1 blockade 
therapy(p = 0.4206), as was PD-1 expression on per cell  basis (p = 0.6991) .  
Taken together, our data suggested that while eight days of anti-PD-L1 
antibody blockade may correlate with recruitment of more non-activated T cells into 
the tumor microenvironment, therapy had no significant effect on activation of T cells 
within the affected tissue as assessed by expression of the IL2 transgene, as well as 
the expression of CD69, ICOS and PD-1. This data suggested that T cell activation 
in the lung is not an accurate predictive marker for responsiveness to anti-PD-L1 
blockade. 
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Figure 9. Eight days of anti-PD-L1 blockade increased T cell density around 
tumors, but did not affect expression of T cell activation markers. A) Activated 
(IL2p8-GFP, green) and non-activated (CD2-RFP, red) T cell densities were 
enumerated from micrographs taken of MCA fibrosarcoma tumor nodules (blue) 
from untreated mice (left) or mice receiving αPD-L1 antibody (right).  Micrographs 
show characteristic swarming of T cells around tumor nodules.   Quantification of T 
cell density around tumors reveals significantly higher densities of non-activated T 
cells (red in micrographs) around tumor nodules from treated mice compared to 
tumor nodules from untreated mice.  No significant difference in activated T cell 
density (green in micrograph) nor the ratio of activated to non-activated T cells 
around tumor nodules could be seen.  Images were acquired using a 20X objective 
(0.70 NA) Z-step = 2 µm.  B)  To look for the presence of CD4+ and CD8+ T cells 
within the lungs, FACS analysis was performed on CD2-RFP mice.  RFPhigh cells 
were gated and analyzed for CD4 and CD8 expression (far left plots). Eight days of 
anti-PD-L1 therapy did not significantly alter the presence of CD4 or CD8 T cells, nor 
the ratio of CD8 to CD4 T cells within the lung. C)  Eight days of antibody therapy did 
not significantly alter expression of PD-1, CD69, or ICOS on CD 4+ T cells.  D) 
CD8+ T cell expression of PD-1, CD69, and ICOS were also not significantly altered 
by 8 days of anti-PD-L1 blockade therapy. Analysis was performed on a total of n=6 
mice per group using a Mann-Whitney U-Test. Error bars represent mean +/- 
standard deviation. ** = p< 0.01, ns= not significant.     
 
 
62 
 
4. T cell dynamics in the tumor microenvironment 
4.1 Assessment of dynamic behavior patterns in the tumor microenvironment. 
Taking into consideration that the activation state of T cells in the tumor 
microenvironment did not correlate with the responsiveness of tumors to PD-L1 
blockade therapy, we next hypothesized that PD-L1 immunotherapy in fact altered T 
cell behavior patterns in the tumor microenvironment which would account in part for 
tumor rejection.  In order to test this hypothesis MCA/mcer fluorescent fibrosarcoma 
tumors were injected into mice expressing the transgenes for activated T cells 
(IL2p8-GFP+), non-activated T cells (CD2-RFP+), and dendritic cells (CD11c-YFP+) 
(see methods) in order to explore the dynamic interplay between these immune cells 
and the tumor.  Immune cell interactions in the tumor microenvironment were very 
heterogeneous. (Supplementary Movie 1, see Appendix).  Dendritic cells exhibited 
little translational motion and tended to cluster around the tumor while both activated 
and non-activated T cells exhibited an amalgam of different behavioral modalities. 
Some T cells clustering around dendritic cells, while other T cells moved around the 
periphery of the tumor and yet others did not interact at all with the tumor nodule.  
After eight days of anti-PD-L1 blockade, immune cells in the tumor 
microenvironment moved in dynamic behavior patterns similar to those seen in 
untreated mice (Supplementary Movie 2, see Appendix).  Tracking software, used 
to probe deeper into motility parameter analysis (81) (Figure 10A),  revealed that  
the  mean velocity (Figure 10B) of pooled activated T cells stood at 1.26 μm/min.,     
matching the mean velocity of  pooled non-activated T cells from tumor bearing mice  
(p = 0.9355).  However, after eight days of anti-PD-L1 immunotherapy, pooled 
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activated T cells exhibited a median velocity of 1.08 μm/min and pooled non-
activated T cells showed a median velocity of 1.32 μm/min (p = 0.0011). Our data 
suggested that PD-L1 blockade may have small effects on T cell behaviors in the 
tumor microenvironment which require deeper analysis of T cell interactions in order 
to elucidate mechanisms by blockade influence tumor immune surveillance. 
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Figure 10. Analysis of T cell migration velocities in lung tumors in vivo in 
response to anti-PD-L1 antibody. A) Fluorescent lung tumors from anesthetized 
mice bearing the CD2-DsRed, IL2p8-GFP, and CD11c-YFP transgenes were 
imaged for one full hour (20X objective, NA 0.70, sequential laser scanning, z-step = 
2 μm) after receiving one week of anti-PD-L1 antibody or PBS as a control.  
Individual cells were tracked over time and several different motility parameters were 
derived. B) Pooled median velocity was similar between activated (IL2-p8-GFP+) T 
cells and non-activated (CD2-DsRed) T cells (left graph).  However, after one week 
of anti-PD-L1 therapy, a significant difference in mean velocity between activated 
and non-activated T cells was seen (right graph). Analysis was performed on a 
minimum of three movies per group. Statistical significance was determined using a 
Mann-Whitney U-Test. Circles indicate individual cells.  Bars indicate median values. 
**= p<0.01, ns = not significant.         
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4.2 T cells remained confined in the tumor microenvironment during PD-L1 
blockade 
Next, we investigated the effect of PD-L1 blockade on the populations of 
activated and non-activated T cells. After eight days of therapy, the pooled median 
velocity of activated T cells was similar to activated T cells from control mice (p = 
0.1246) as were arrest coefficients (p = 0.7242) (Figure 11A).  Spider-plots of T cell 
tracks (Figure 11B, D) revealed that activated T cell tracks from either treated or 
untreated mice  were densely confined around a point of origin, traveling no more 
than a few T cell lengths (Figure 11B).  
Similar to activated T cells, the median velocity of pooled non-activated T 
cells after eight days of therapy was comparable to the median velocity of untreated 
controls (p = 0.4647) (Figure 11C).  However, the arrest coefficients of non-
activated T cells were reduced after eight days of anti-PD-L1 therapy (p = 0.0321) 
(Figure 11C).  Analogous to activated T cells, spider-plots of non-activated T cell 
tracks revealed heavy confinement (Figure 11D). However, low median velocities 
(less than 2 μm/min) and high median arrest coefficients (greater than 0.75) along 
with evidence of limited motility from spider plots led us to hypothesize that T cells 
were heavily engaged in interactions in the tumor microenvironment.  Upon further 
investigation of potential targets of engagement, we found that T cell tracks 
overlapped in large part with DC in the tumor microenvironment (Figure 11E).   
Together these data suggested that both activated and non-activated T cells in the 
tumor microenvironment engage in tightly confined motility patterns, with DC being a 
potential focus of confinement.  
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Figure 11. T cells were confined in the tumor microenvironment. A) The median 
velocity (left) and arrest coefficients (right) of pooled activated T cell were 
unchanged after 8 days of anti-PD-L1 therapy. B) Activated T cells from both treated 
and untreated mice were densely confined in the tumor microenvironment as 
indicated from spider-plots which indicated that T cells travel no further than a few T 
cell lengths. C) The median velocity (left) of pooled non-activated T cells was not 
significantly altered by therapy, however, arrest coefficients (right) from the pool of 
non-activated T cells were significantly lower after 8 days of PD-L1 blockade 
therapy. D) Non-activated T cells traveled only short confined distances as indicated 
by spider-plot analysis. E)  Confined T cell motility patterns overlapped with CD11c-
YFP+ dendritic cells within the tumor microenvironment (white arrows). Images 
taken using a 20X objective (NA 0.70, z-step = 2 µm) Motility analysis performed on 
a minimum of 3 independent experiments. Statistical significance was determined 
using a Mann-Whitney U-Test. Bars indicate median values.  ** = p<0.01, ns = not 
significant.    
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4.3 Non-activated T cells interacted preferentially with dendritic cells during    
PD-L1 blockade. 
 We next hypothesized that confined T cell motility patterns correlate to 
interactions with various types of cells in the tumor microenvironment.  Furthermore, 
PD-L1 blockade would modulate these interactions, leading to enhanced tumor 
surveillance and tumor killing.  To explore this hypothesis, we developed an image-
analysis based method which allowed us to define T cell interactions and quantify 
what types of cells with which T cells interacted.   
 In order to quantify T cell interactions in the tumor microenvironment using an 
imaging-based approach, we employed the Leica Application Suite to process 
images (see methods). Maximum intensity time projections (MITPs) were 
thresholded to represent all areas where a cell visited during a motility recording. 
(Figure 12A, left micrograph) Average intensity time projections (AITP) were 
thresholded to an intensity value of 43; representing sites were cells persisted for 10 
or more minutes (Figure 12A, right micrograph).  MITPs and AITPs were then 
merged into a single image (Figure 12A, bottom micrograph).  Areas of 
fluorescence overlap (yellow) indicate sites of cellular persistence.  Each cell in the 
micrograph was then carefully enumerated (Figure 12B).  Large areas of 
overlapping fluorescence were carefully analyzed in the original MITP to find the 
exact number of cells contained in the overlapping section (Figure 12B, left 
micrograph).  
71 
 
Next, each merged image was compared to the original movie file in order to 
correlate areas of persistent confinement with potential cellular targets in close 
proximity.  Cellular persistence was classified as an interaction in close proximity 
with either: DC only, with tumor only, with DC and tumor, or with neither DC nor 
tumor.  To reiterate, an interaction was defined as a T cell with overlapping 
fluorescence in the merged image (yellow) in close proximity (within one T cell 
length) of an interacting partner.  T cell interactions were then categorized and 
enumerated for both activated and non-activated T cells taken from one hour 
recordings of T cell motility around tumor nodules from either untreated mice or mice 
treated for 8 days with PD-L1 blocking antibody (Figure 12C). T cells with no 
overlapping fluorescence (1, 2, 3 in 12C) did not make stable engagements and left 
the viewing area (Supplementary movie 3, see appendix) and did not count 
toward T cell interactions.  T cells also made stable interactions with non-DC/non-
tumor cells (6, 7, 8 in 12C), with DC only (26, 27, 31, 35), or with both DC and tumor 
(19, 40 in 12C) (see Supplementary Movie 3 in appendix for clarification).      
By  quantifying the percent of T cells in each image sequence with persistent 
interactions in each target category, we found that 40-50% of both activated and 
non-activated T cell interactions occurred with both DCs and the tumor (Figure 
12D). Non-activated T cells appeared to interact slightly more than activated T cells 
with neither tumor nor DC.   
Next we sought to determine whether eight days of anti-PD-L1 blockade 
therapy had any effect on the T cells making stable interactions with either dendritic 
cells or the tumor itself.  While activated T cells made similar preferential interactions 
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with DC and tumor targets during PD-L1 treatment compared to controls, (Figure 
12E, left panel), non-activated T cells made more preferential interactions with DC 
partners when treated with anti-PD-L1 blocking antibody, (19% vs. 35% p = 0.0286) 
(Figure 12E right panel). 
While it appeared that non-activated T cells made more preferential 
interactions with DC during anti-PD-L1 therapy, this affect could simply have been 
caused by an effect of PD-L1 blockade the ability of DC to engage the tumor. To 
explore this possibility, we analyzed DC contacting the tumor in both untreated and 
anti-PD-L1 treated mice.  On average, 58% of DC were in contact with the tumor, 
and anti-PD-L1 blockade therapy did not significantly release DC from tumor 
engagements (p = 0.3429) (Figure 12F).  Our data show that while activated T cells 
had no significant preference for interacting partner during anti-PD-L1 blockade, 
non-activated T cells greatly preferred DC-only interactions in the tumor 
microenvironment during blockade. This suggested that non-activated T cells may 
be making more positive engagements with DC, perhaps to gain activation signals 
as opposed to tumor-killing interactions at the tumor site.  
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Figure 12. Quantification of T cell interactions in the tumor microenvironment. 
A) T cell interactions in the tumor microenvironment were quantified using the Leica 
Application Suite image processing software. Maximum intensity time projections 
(MITPs) represent areas where T cells visited throughout the entire image 
sequence. Average intensity time projections (AITPs) were thresholded to represent 
areas where T cells persisted for 10 minutes or longer. These two images were then 
merged to create areas of overlapping intensities indicating areas of T cell 
persistence. B) Areas of T cell persistence were then individually enumerated and 
(C) compared to the original hour long movie to determine with which cell types T 
cells were in close proximity.  These areas were then classified as interactions.  D) T 
cell persistent interactions were then categorized as interactions with DC, with 
tumor, with tumor and DC, or with neither tumor nor DC, and quantified for both 
activated and non-activated T cells.  Both T cell types interacted heavily with DCs, 
whether in DC only interactions or DC and tumor interactions.  E)  During PD-L1 
therapy, activated T cells made similar types of interactions compared to controls.  
However, non-activated T cells showed a significantly greater preference for DC only 
interactions in the tumor microenvironment compared to non-activated T cells from 
untreated mice.  F) This increased preference was not due to an effect of PD-L1 
blockade on the ability of DC to contact the tumor as the total number as well as 
percent of DC contacting the tumor was similar in treated and untreated mice.  
Analysis was from n=4 movies per group. Statistical significance was determined 
using a Mann-Whitney U-Test to compare percent of interactions within each 
category. Bars represent median values. * = p<0.05, ns = not significant. 
77 
 
4.4 Activated T cells formed more stable contacts with DC during anti-PD-L1 
blockade therapy. 
 The vast majority of T cell interactions with dendritic cells in the tumor 
microenvironment (with DC contacting the tumor or with DC alone) suggested that T 
cells were receiving signals from dendritic cells. We hypothesized that PD-L1 
blockade was modulating these T cell/DC interactions. To explore this hypothesis, 
we sought to evaluate whether the sites of T cell confinement correlate with the 
localization of DC in lung tumors. By plotting the mean displacement of a large pool 
of T cells vs. the square root of time, three distinctly different T cell motility patterns 
can be deciphered (81) (Figure 13A).  A linear function with positive correlation 
would indicate T cell motion in a random fashion, as T cells move indiscriminately 
around a target (Figure 13A, left top and bottom).  A quadratic function of T cell 
displacement suggests T cells move in a directional pattern toward a target in a 
chemokine driven manner (Figure 13A, middle top and bottom).  A logarithmic 
function would indicate that T cells are engaging in confined motility patterns and are 
being kept confined in a chemokine-driven manner (Figure 13A, right top and 
bottom). If the scale of displacement is sufficiently small, T cell confinement would 
indicate stable cell-cell engagement with the target.  Larger displacements would 
indicate that T cells may be confined to larger areas around their targets, being kept 
in a broader area in a chemokine-dependent fashion. 
 Logarithmic functions of displacement graphs indicated that both activated 
and non-activated T cells exhibited confined motility in the tumor microenvironment, 
lending further support to previous findings of T cell confinement (Figure 13 B, C). 
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Displacement on the scale of tens of micrometers indicated tight cell-cell interactions 
as opposed to broad patrolling behavior. After 8 days of anti-PD-L1 therapy, 
activated T cells exhibited smaller displacements over time than activated T cells 
from control mice (Figure 13B, left).  T cell track straightness (Figure 13B, right), a 
measure of the ratio between a T cell’s displacement and its track length, confirm 
reduced T cell displacements, as T cells from treated mice displayed median track 
straightness of 0.12 units compared to T cells from untreated mice which displayed 
median track straightness of 0.26 units, p < 0.001 (Figure 13B, right). 
Non-activated T cells also displayed logarithmic displacement curves 
indicating T cell confinement on the scale of tens of micrometers, indicating cell-cell 
interactions which were on the order seen in activated T cell from anti-PD-L1 treated 
mice (Figure 13C, left). T cell track straightness (0.17 units) was not significantly 
altered by anti-PD-L1 therapy, p = 0.1241 (Figure 13C, right).        
We next sought to correlate the higher confinement of activated T cells from 
mice treated anti-PD-L1 antibody with actual motility in vivo.  Activated T cells 
interacted in close proximity to DC in the tumor microenvironment in untreated mice 
(Supplementary movie 4, see Appendix). These interactions were very loose 
sliding motions as T cells moved around and over DC.  However, activated T cells 
from anti-PD-L1 treated mice engaged in tighter, more stable interactions with 
limited movement around DC (Supplementary movie 5, see Appendix).  These 
results were in line with displacement graphs (Figure 13B) demonstrating higher T 
cell displacements in untreated mice and lower T cell displacements in mice treated 
with anti-PD-L1 antibody.    
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Our data showed that, as a consequence of PD-L1 blockade, activated T cells 
engaged in more tightly confined, stable interactions, particularly with DC in the 
tumor microenvironment, whereas activated T cells engaged with  DC in looser, less 
stable interactions when PD-L1 was able to engage its receptors. This data 
suggested that PD-L1 interactions with PD-1 on T cells may prohibit T cells from fully 
engaging DC and may prevent T cells from receiving long term activation signals.  
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Figure 13. Activated T cells engaged in stable interactions with DC in the 
tumor microenvironment in response to PD-L1 blockade. A)  Graphs of  T cell 
mean displacement indicate distinct T cell motility patterns.  Linear functions indicate 
random motility around a target cell.  Quadratic functions indicate directional 
movement of T cells toward a target in a chemokine-dependent manner.  
Logarithmic functions indicate confined motility around a target that may indicate 
tight cell-cell interactions if displacements are low or larger patrolling behaviors if 
displacements are sufficiently large. B) Activated T cells displayed confined 
displacements on a small scale, indicating tightly confined cell-cell interactions.  
Activated T cells during anti-PD-L1 treatment displayed reduced displacements 
(left), and exhibited reduced track straightness (right) compared to activated T cells 
from controls.  C) Non-activated T cells displayed confined displacements on a small 
scale, indicating tight cell-cell interactions similar to activated T cells during PD-L1 
blockade.  Displacements (left) nor track straightness (right) were not significantly 
altered by anti-PD-L1 therapy.  Analysis from n= 3 movies per group. Displacement 
graphs represent mean +/- SEM.  Bars in track straightness plots represent median 
values.   *** = p < 0.001, ns = not significant.     
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5. Discussion 
5.1 Anti-PD-L1 therapy 
Anti-PD-L1 blocking antibody is already being used in Phase II clinical trials 
for the treatment of late stage cancers including melanoma, non-small-cell lung 
cancer, and renal cell carcinoma.  Patients with objective responses to this 
immunotherapy have shown at the very least stable disease progression and in the 
most promising cases, complete tumor regression lasting for months or even years 
(56).  While patients receiving the treatment exhibited minimal immune-mediated 
adverse reactions (imAR) (82), and responses are impressive, only a fraction of 
patients receiving anti-PD-L1 therapy alone responded to treatment (56). Work has 
also tried to elucidate any benefit of combinatorial therapies with the anti-CTLA4 
antibody Ipilimumab for melanoma (60, 83, 84), however, a better understanding of 
the biology of PD-1/PD-L1 interactions is key to improving the response rates of 
patients to anti-PD-L1 therapy. 
 To study the role of PD-L1 in immune suppression in the tumor 
microenvironment, our lab used a commercially available rat anti-mouse blocking 
antibody that blocked both the binding epitope for PD-1 as well as CD80 on the PD-
L1 molecule (51). Using a novel approach to image tumor in the lungs, we analyzed 
the total amount of tumors engrafted on the lung surface at various time points 
during tumor progression and found that MCA induced fibrosarcomas from mice 
receiving anti-PD-L1 antibody regressed after three weeks of treatment.  This 
method had its advantages over conventional methods (e.g. calipers) which require 
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that tumors be 1) visible to the human eye, 2) of a large enough size to measure, 
and 3) easily accessible to measurement of tumor size. These methods typically do 
not take into account smaller, unseen tumors and may be subject to selection bias. 
Our novel method, allowed visualization of a broad picture of engraftment of even 
microscopic tumors throughout the entire lung as well as a broader sense of the 
entire scope of tumor coverage in an organ. One key drawback, though, was the 
depth of tissue penetration as only surface nodules within 200 μm of the surface 
could be visualized.  However, current microscopy-based techniques are seeking to 
improve the depth and resolution of tissue imaging (85, 86). 
Using a novel imaging-based approach to elucidate the “tumor roundness 
index”, changes in tumor morphology as a result of anti-PD-L1 therapy were easily 
visualized and quantified.  Increased tumor roundness during PD-L1 blockade 
suggested a potential mechanism by which tumors are first contained early during 
PD-L1 blockade before later tumor clearance.  It would be interesting to see if this 
observed increase in tumor roundness after 8 days of anti-PD-L1 therapy continued 
throughout the entire course of treatment, which would solidify our hypothesis. 
Furthermore, it remains to be seen whether tumors completely regress during PD-L1 
blockade or return after cessation of treatment.  If this were indeed the case, then it 
would be interesting to see whether mice were immunized against the tumor after 
receiving the therapy and would therefore be able to effectively eliminate tumors 
upon re-challenge.  
 We also showed that some, but not all, tumors expressed PD-L1 in vivo 15 
days after tumor injection (Figure 5).  It would be of interest to determine whether 
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tumors further upregulate PD-L1 as tumors continued to grow or if there is a 
selective advantage of PD-L1+ tumor survival in the lung over time. We also 
observed heterogeneity in recruitment of T cells to tumor nodules.  Thus, it would be 
of value to determine the mechanism by which some T cells were recruited in 
abundance to some tumor nodules while other nodules recruited fewer T cells, and 
whether PD-L1 expression played a role in this heterogeneity.  In addition, we found 
that PD-L1 is expressed at low levels on MCA fibrosarcomas in vitro, but much 
greater in vivo.  We showed that IFN-γ, in line with other reports (46), upregulated 
PD-L1in vitro.  Our findings that PD-L1 was expressed in vivo but not in vitro 
suggested that immune cells in the tumor microenvironment may produce IFNγ in 
response to the tumor. We would like to confirm this, as well as look at other effector 
responses by T cells in vivo.  
5.2 Immune cell characterization 
 Strikingly, a majority of PD-L1 was expressed on stromal cells in the tumor 
microenvironment, including myeloid derived suppressor cells (MDSCs), tumor 
associated macrophages (TAMs), inflammatory DCs and conventional DCs (cDCs).  
To our knowledge this is the first report that has begun phenotyping PD-L1+ immune 
cells in the tumor microenvironment and the effect of PD-L1 blockade on these 
immune populations.  We showed that the majority of dendritic cells (both 
inflammatory DC and cDC) express PD-L1.  The expression of PD-L1 and the 
inhibitory receptor PD-1 on a large portion of inflammatory DC further support their 
function as suppressors (22, 23).  The large percentage of PD-1+ and PD-L1+ 
conventional DC would also suggest that these DC may be suppressive as well (24) 
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though their function remains to be determined.  We found that anti-PD-L1 therapy 
A) did not significantly alter recruitment of any of the myeloid cells tested into the 
peripheral lung tissue and B) blocked available PD-L1 on all of the myeloid cell 
populations tested without significantly altering the expression of the costimulatory 
B7 molecules or the inhibitory receptor PD-1.  We found a trend in the reduction of 
the percent of MDSC in the lungs after 8 days of therapy (p = 0.0688), as well as a 
trend in lower MFI of the expression of both PD-1 (p = 0.0688) as well PD-L1 on 
TAMs (p = 0.0632).  It would be interesting to determine whether these trends 
become significantly different over the treatment period, and would thus suggest 
another mechanism by which anti-PD-L1 therapy effectively led to tumor regression.  
Moreover, each of these myeloid cell populations need further phenotypic 
characterization in order to further differentiate each population as well as to 
determine if the expression of other markers could be affected by anti-PD-L1 
therapy.  Plasmacytoid dendritic cells (pDCs) which have been shown to express 
PD-L1 and play an important role in immune regulation (87) need also be 
characterized to determine how their role in immune surveillance is altered, if at all, 
during PD-L1 blockade.  A relatively new marker added to further characterize the 
B220+CD11c+ plasmacytoid dendritic cell population is the marker Gr-1 (88) which 
has generally been used to characterize MDSC (77). While we observed a Gr-1+ 
population within the CD11b-CD11c+ conventional DC population, it would be 
premature to call these cells plasmacytoid DC before further phenotypic analyses 
were conducted.   
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 Several groups have noted the effect of anti-PD-1 or anti-PD-L1 blockade on 
T cell activation and motility in the lymph nodes (60) (70),  however, little has been 
done to assess the effect of PD-L1 blockade on T cells within peripheral tissue, 
especially in response to tumors.  In agreement with one report (89), we showed that 
during blockade/inhibition of PD-L1, T cells more heavily infiltrated into the 
microenvironment.  Within 8 days of PD-L1 blockade therapy, non-activated T cells 
swarmed more densely around tumors than non-activated T cells from controls.  
This additional recruitment of non-activated T cells as early as eight days of 
treatment may contribute to tumor regression.  A similar increase in density for 
activated T cells was not observed; however, this may be due to the relative paucity 
of activated T cells in the tumor microenvironment compared to non-activated T 
cells.  It would be of interest to ascertain whether T cells could be activated in the 
tumor microenvironment or if activated T cells are instead recruited from the lymph 
nodes. Of similar interest would be to determine whether PD-1/PD-L1 interactions in 
the tumor microenvironment prevent non-activated T cells from being activated 
and/or maintaining activation. Moreover, how the total numbers and densities of 
activated and non-activated T cells changed over the entire course of treatment 
should be investigated particularly whether T cells were recruited later in controls or 
not at all.  For example, if response time were a factor the ability of the immune 
system to control tumor growth, T cells may in fact form similar dense clusters 
around tumors in control mice; however T cell recruitment into the tumor 
microenvironment may be delayed until tumor progression is beyond control. 
Therefore, PD-L1 blockade may disable a mechanism that would prevent T cells 
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from infiltrating the tumor microenvironment at higher densities around nodules 
much earlier the time course of tumor progression when the tumors can still be 
controlled and eliminated.  Future experiments would be needed to determine if 
earlier T cell recruitment would in fact contribute to tumor elimination. 
 We next sought to determine whether anti-PD-L1 therapy affected recruitment 
of cytotoxic CD8+ T cells as a means to lyse tumors or CD4+ helper T cells as a 
means to stimulate T cell anti-tumor responses and likewise whether therapy altered 
the stage of activation (early, intermediate or late stage) of these cells the lung 
tissue.  Eight days of therapy did not significantly alter the portions of CD8+ or CD4+ 
T cells in the lung, nor were indicators of early (CD69), intermediate (ICOS), or late 
stage (PD-1) activation significantly affected in either T cell population.  Future 
experiments need shed light on any possible temporal aspect of T cell recruitment 
and activation. For instance, it would be interesting to assay for T cell recruitment at 
other time points during the treatment protocol as cytotoxic or helper T cells may 
arrive earlier during PD-L1 therapy or increase in the peripheral tissue following 
eight days of PD-L1 blockade and likewise, T cell may stay active longer in the lung 
of mice treated with PD-L1 blockade.  Future experiments are needed to determine if 
this is the case.  Along with T cell activation, it would be worthwhile to look at how 
PD-L1 blockade affected the production of effector molecules by T cells (granzymes, 
perforins, interferon-γ, etc).  Insight could then be gained into the relative roles and 
importance of tumor killing by cytotoxic T cells as well as T cell support offered by a 
variety of cells including helper T cells, B cells, and dendritic cells in the tumor 
microenvironment.   It should also be noted that CD8 T cells are not the only killers 
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in the tumor microenvironment; NK cells (90) as well as NKT cells (91, 92) also 
contribute to tumor killing. 
5.3 T cell motility and interactions in the tumor microenvironment    
 Our data suggested that phenotypic analysis of immune cells in the peripheral 
tissue was not a sufficient indicator of response to anti-PD-L1 therapy, hence we 
hypothesized that a change in T cell dynamics in the tumor microenvironment due to 
PD-L1 blockade contributed to effective tumor clearance.  The heart of my thesis 
revolved around this hypothesis and in the analysis of T cell motility in the tumor 
microenvironment.  T cells, both activated and non-activated, exhibited slow, 
confined motility patterns in the tumor microenvironment.  Contrary to findings in the 
lymph where T cells were shown to reduce their velocity during anti-PD-L1 blockade 
(70), or in the spleen where T cells were shown to increase their velocity during viral 
infection (93), we found that PD-L1 blockade did not significantly impact T cell 
velocity in the tumor microenvironment compared to controls. This was most likely 
on account of low T cell mobility (as indicated by low mean velocities and high arrest 
coefficients) in the tumor microenvironment prior to and including 15 days after 
tumor injection which suggested that T cells were engaged in interactions in the 
tumor microenvironment.  
However, current methods poorly define a T cell “interaction”.  Often times 
“interaction” is simply defined in an in vivo system as contact with a second cell type 
(67), or exhibiting an effector function (63) with little progress in truly defining or 
quantifying T cell interactions in the tumor microenvironment.   
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To better understand T cell interactions in the tumor microenvironment, we 
developed a novel, imaging-based approach to quantify T cell interactions in the 
tumor microenvironment.  Using this method, both activated and non-activated T 
cells were revealed to engage heavily with dendritic cells in the tumor 
microenvironment, whether with dendritic cells alone or with dendritic cells and the 
tumor itself.  When mice were treated with anti-PD-L1 antibody for eight days, non-
activated T cells made more preferential DC only interactions, whereas activated T 
cells showed no such preference for any interacting partner, but activated T cells 
were more tightly confined in stable immune synapse-like interactions with dendritic 
cells in the tumor microenvironment.  Our data suggested that while PD-L1 blockade 
appeared to have affected both activated and non-activated T cells at a microscopic 
level, therapy appeared to have more influence on non-activated T cells.  It is 
tempting to speculate on the implications of PD-L1 blockade on the dynamics of 
each of these populations in the tumor microenvironment.  It appeared that non-
activated T cells were being recruited in larger numbers during therapy (as indicated 
by higher T cell densities), were making more transient interactions (indicated by 
reduced arrest coefficients), and more of these interactions were occurred 
preferentially with DC in the tumor microenvironment. Further experiments would be 
needed to verify whether non-activated T cells were quickly scanning for antigen as 
our results suggested by reduced arrest coefficient and whether these cells were 
gaining activation signals from dendritic cells in the tumor microenvironment.   If this 
were found to be the case, it would be beneficial to identify these activation signals.  
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Activated T cells made more stable immune-synapse-like interactions with 
dendritic cells in the tumor microenvironment during PD-L1 blockade as opposed to 
activated T cells from control mice which appeared to engage in  brief immune-
kinapse-like interactions with dendritic cells (14). Taking all of our dynamic T cell 
motility data into account we developed a model (Figure 14) by which 1) non-
activated T cells were recruited in higher numbers during PD-L1 blockade, engaged 
DC more preferentially (potentially to receive activation signals), and arrested for 
less time (potentially to scan for antigen); and 2) activated T cells were recruited in 
the same number into the tumor microenvironment but were able to make more 
stable synapses with DC during PD-L1 blockade (potentially receiving a stronger 
activation signal) (16). Further experiments would need to determine whether 
signaling complexes were recruited to form a synapse and to determine the strength 
of TCR signaling.  It would also be interesting to further phenotypically characterize 
the  activated T cells as well as the non-activated T cells making contacts with DC, 
as well as further characterization of the DC making contacts in the tumor 
microenvironment. 
Taken together, we showed that anti-PD-L1 therapy worked to 1) allow 
activated T cells to make more stable interactions with dendritic cells in the tumor 
microenvironment, 2) recruit more non-activated T cells into the tumor 
microenvironment which make more preferential interactions with dendritic cells.  A 
combination of these two factors may act synergistically to contribute to tumor 
regression.   
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Figure 14. 
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Figure 14. Model for T cell interactions with dendritic cells in the tumor 
microenvironment. PD-L1 may have differential effects on activated and non-
activated T cells in the tumor microenvironment. During tumor progression (left), 
activated T cells (green) and nonactivated T cells (red) were recruited into the tumor 
microenvironment and engaged in heterogeneous interactions with either the tumor 
(blue) or dendritic cells (DC) (yellow) in the tumor microenvironment. Activated T 
cells (T cell “A” in left inset) formed unstable immune kinapse-like interactions 
characterized by mobile interactions (arrow) with DC. Both activated and non-
activated T cells may be receiving activation signals (+ in figure), though this is yet to 
be determined.  However, during PD-L1 blockade (right), non activated T cells were 
recruited in higher densities and engaged preferentially with dendritic cells (T cell “B” 
in right inset). Activated T cells (T cell “A” in right inset) were not preferentially 
recruited, but were able to maintain stronger, more stable immune synapse-like 
interactions with DC in the tumor microenvironment. Both activated and non-
activated T cells potentially received stronger activation signals (+ in right inset), 
though this still needs to be determined.   
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5.4 Implications of our novel method on future research 
 Our novel method of imaging-based quantification of immune cell interactions 
was useful in elucidating T cell interactions, but this method can be broadly applied 
to other fields.  Study of interactions now need not be solely studied in vitro or ex 
vivo; interactions which may not be truly applicable to true in vivo dynamic 
behaviors.  With this novel method, true interactions can be observed and quantified 
in vivo.  Of course, this method would need to be combined with further analysis of 
adhesion molecules and cellular signaling to ensure that interacting cells were stably 
engaged, but our method is a novel, unique tool that can be added to the tool-bag of 
image analysis.        
5.5 Implications on immune therapy 
 Our findings have broad implications on cancer immunotherapy.  We showed 
that early tumor biopsies may not clearly indicate patient response rate.  T cells in 
the tumor microenvironment showed no significant difference in the particular 
activation phenotypes tested.  Nor were the phenotypes of myeloid cells significantly 
different at early stages.  This finding reveals the importance of looking at the bigger 
picture of immune cell dynamics in the tumor microenvironment in order to ascertain 
whether a patient will respond to therapy.  Potentially, tools need to be developed 
which would include immune cells dynamics as a prognostic indicator of response 
rates.  
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6. Appendix 
Supplementary Movie 1.  Dynamic immune cell motility patterns in tumor 
bearing mice.  Activated T cells (green) as well as non-activated T cells (red) 
engaged in a heterogeneous mixture behavior patterns with both dendritic cells 
(white) and tumor nodules (blue) in tumor bearing mice.  Some T cells engage the 
tumor.  Other T cells engaged dendritic cells, while others move quickly in and out of 
frame without engaging any targets.   This movie is one representative 45-minute-
long movie from a total of four movies taken from four different mice ranging from 45 
minutes to one hour long.  This movie was taken using 20X objective (0.70 NA), Z-
step size = 2 μm, utilizing sequential scanning with a 20 second scan time.  
Supplementary Movie 2. Dynamic immune cell behaviors in tumor bearing 
mice receiving anti-PD-L1 antibody blockade. After 8 days of anti-PD-L1 antibody 
therapy, activated T cells (green) and non-activated T cells (red) exhibit complex 
behavior patterns with dendritic cells (white) and tumor nodules (blue). T cells 
demonstrate a mixture of behaviors ranging from contacting the tumor nodule, 
dendritic cells, other T cells, or no other visible cell type. Movie is one representative 
one-hour-long movie from a total of four movies taken from four different mice, taken 
using a 20X objective (0.70 NA), Z-step size = 2 μm, utilizing sequential scanning 
with a 20-second scan time. 
Supplementary Movie 3. Interactions in the tumor microenvironment.  Complex 
interactions in the tumor microenvironment were broken down using a novel 
imaging-based analysis technique (Figure 7B,C). Cells with persistent motility 
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characterized by overlapping binarized fluorescence were enumerated and 
interactions, defined as persistent motility within one T cell length of a second cell 
type, were quantified. Cells were categorized as interacting with dendritic cells alone 
(middle bottom), tumor alone, dendritic cell and tumor together (left middle), or 
neither dendritic cell nor tumor (upper right corner).  Cells without overlap (upper left) 
were motile and did not stably interact with a partner. This movie is one 
representative one-hour-long movie from a total of four movies taken from four 
different mice.  The movie was taken using a 20X objective (0.70 NA), Z-step size = 
2 μm, utilizing sequential scanning with a 20 second scan time.  
Supplementary Movie 4. Activated T cells engaged in unstable interactions 
with dendritic cells in the tumor microenvironment.  Activated T cells (green) 
from control mice made unstable, sliding interactions with dendritic cells (red) 
surrounding the tumor (blue). One representative 45-minute-long movie taken of four 
one hour long movies from four different mice is shown. Movies were taken using an 
20X objective (0.70 NA) , Z-step size = 2 μm, utilizing  sequential scanning with a 20 
second scan time. 
Supplementary Movie 5.  Activated T cells engaged in stable interactions with 
dendritic cells in the tumor microenvironment during PD-L1 blockade.  
Activated T cells (green) from mice receiving one week of anti-PD-L1 antibody 
therapy made strong, stable engagement with dendritic cells (red) in surrounding the 
tumor (blue).  One representative one-hour-long movie taken of four from four 
different mice. Movies were taken using an HCPL APO 20X/0.70 NA objective, Z-
step size = 2 μm, sequential scanning using a 20-second scan time. 
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